by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia
Abstract INTRODUCTION ABBV-916, an anti-amyloid immunotherapy, was evaluated in patients with early Alzheimer’s disease (AD). METHODS This phase 1b/2, double-blind, placebo-controlled study consisted of two stages: multiple ascending dose (Stage A) and dose...
by Clinical Neuropsychologist Online | Thursday, August 6, 2026 | Dementia
Dementia, Ahead of Print. Background:Primary Progressive Aphasia (PPA) is a rare condition characterised by a gradual loss of language due to neurodegenerative processes including frontotemporal lobar degeneration and Alzheimer’s disease. Speech and language therapy...
by Clinical Neuropsychologist Online | Thursday, August 6, 2026 | Dementia
Abstract INTRODUCTION We evaluated lecanemab’s safety and cognitive outcomes in Chinese patients with Alzheimer’s disease (AD) and the utility of blood-based biomarkers (BBMs) for treatment guidance. METHODS A multicenter, real-world cohort enrolled 1042...
by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia
Abstract INTRODUCTION Animal models demonstrated that pharmacologically-induced lesioning of the locus coeruleus (LC), the brain’s primary source of norepinephrine, triggered astrocyte reactivity, exacerbating Alzheimer’s disease (AD) pathology and...
by Clinical Neuropsychologist Online | Wednesday, August 5, 2026 | Dementia
Abstract INTRODUCTION Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal phase of Lewy body diseases and linked to a high risk for cognitive decline. Therefore, iRBD provides a suitable window for early intervention. METHODS In the...
